Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1

Archive ouverte

Weber, Axel | Schwarz, Sigrid, C. | Tost, Jorg | Trümbach, Dietrich | Winter, Pia | Busato, Florence | Tacik, Pawel | Windhorst, Anita | Fagny, Maud | Arzberger, Thomas | Mclean, Catriona | van Swieten, John | Schwarz, Johannes | Vogt Weisenhorn, Daniela | Wurst, Wolfgang | Adhikary, Till | Dickson, Dennis | Höglinger, Günter | Müller, Ulrich

Edité par CCSD ; Nature Publishing Group -

International audience. Genetic, epigenetic, and environmental factors contribute to the multifactorial disorder progressive supranuclear palsy (PSP). Here, we study epigenetic changes by genome-wide analysis of DNA from postmortem tissue of forebrains of patients and controls and detect significant (P < 0.05) methylation differences at 717 CpG sites in PSP vs. controls. Four-hundred fifty-one of these sites are associated with protein-coding genes. While differential methylation only affects a few sites in most genes, DLX1 is hypermethylated at multiple sites. Expression of an antisense transcript of DLX1, DLX1AS, is reduced in PSP brains. The amount of DLX1 protein is increased in gray matter of PSP forebrains. Pathway analysis suggests that DLX1 influences MAPT-encoded Tau protein. In a cell system, overexpression of DLX1 results in downregulation of MAPT while overexpression of DLX1AS causes upregulation of MAPT. Our observations suggest that altered DLX1 methylation and expression contribute to pathogenesis of PSP by influencing MAPT

Suggestions

Du même auteur

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

Archive ouverte | Höglinger, Günter | CCSD

International audience. Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP...

Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies

Archive ouverte | Respondek, Gesine | CCSD

International audience. Abstract Background The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4‐repeat (4R)‐tauopathy” for joint clinical diagnosis of progre...

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Archive ouverte | Respondek, Gesine | CCSD

International audience. Background: Progressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.Objective: To identify clinical features and ...

Chargement des enrichissements...